# Treatment of Common Cold Patients with the Shi-Cha Capsule: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Trial

Authors: Jing Chang; Shou-Jin Dong; Bin She; Rui-Ming Zhang; Mao-Bin Meng; Yan-Ling Xu; Li-Ling Wan; Ke-Hua Shi; Jun-Hun Pan; Bing Mao
Journal: Evidence-Based Complementary and Alternative Medicine
 (2012)

---

## Abstract

This study was designed to determine the therapeutic efficacy and safety of the Shi-cha capsule, a Chinese herbal formula, in the treatment of patients with wind-cold type common cold. In our multi-center, prospective, double-blind, randomized, placebo-controlled, dose-escalation trial, patients with wind-cold type common cold received 0.6 g of Shi-cha capsule plus 0.6 g placebo (group A), 1.2 g of Shi-cha capsule (group B), or 1.2 g placebo (group C), three times daily for 3 days and followed up to 10 days. The primary end point was all symptom duration. The secondary end points were main symptom duration, minor symptom duration, the changes in cumulative symptom score, main symptom score, and minor symptom score 4 days after the treatment, as well as adverse events. A total of 377 patients were recruited and 360 met the inclusive criteria; 120 patients constituted each treatment group. Compared with patients in group C, patients in groups A and B had significant improvement in the all symptom duration, main symptom duration, minor symptom duration, as well as change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4. The symptom durations and scores showed slight superiority of group B over group A, although these differences were not statistically significant. There were no differences in adverse events. The Shi-cha capsule is efficacious and safe for the treatment of patients with wind-cold type common cold. Larger trials are required to fully assess the benefits and safety of this treatment for common cold.


---

## Body

## 1. Introduction

The common cold is frequent both in the developed and developing countries with the symptom of nasal congestion and discharge, sneezing, mild fever, cough, headache, and malaise, and it is caused by over 200 viruses or bacteria [1–3]. Although the courses are usually benign and self-limited for approximately one week, the high incidence and clinical presentation cost substantial economic burden, due to work absence, physician visit, and over-the-counter drug consumption [4]. It is estimated that an adult may encounter 2 to 4 episodes of common cold every year and physician visit is prompted by clear nasal discharge and congestion, and cough by most patients [5]. Despite the  burden of common cold, no effective etiological treatment and little preventive strategy have been proven. Therefore, current therapy focuses on symptom relief. Although various drugs are available in the market to address the symptoms of cold, solid evidence for recommended therapy is rare due to the quality of studies, adverse effects, or disappointing results [6–13].Traditional Chinese medicine (TCM) is a 3000-year-old holistic system of medicine that combines medical herbs, acupuncture, food therapy, massage, and therapeutic exercise for both extensive treatment and prevention of diseases, including common cold. Dissatisfaction with treatments offered by Western medicine has led many patients to turn to for treating common cold in China and other parts of the world, but the quality of reported studies is of great concern [14]. TCM is a unique system with special etiology and theories for the treatment of common cold according to TCM signs such as avertion to cold, clear nasal discharge, arthralgia of extremities, fever, headache, stuffy nose, sneezing, spiritlessness and weakness, tongue proper, and tongue fur. According to the above symptoms, common cold is categorized as wind-cold type, wind-heat type, as well as summer-heat and dampness type. Among these types, wind-cold type was primarily characterized by avertion to cold and clear nasal discharge, which is treated with “disperse wind-evil and dispel cold as well as supplement Qi(vital energy) for strengthening exterior” according to the fundamental principles of TCM.Shi-Cha capsule (SCC) is a new traditional Chinese prescription and manufactured by the Yunnan Institute of Materia Medica, Yunnan, China. It composes of Shi Jiaocao (Boenninghausenia sessilicarpa), Xiao Shancha (Elsholtzia bodinieri Van), Huang Qi (Astragalus membranaceus), Yu Xingcao (Houttuynia cordata Thunb), Qian Liguang (Climbing groundsel Herb), as well as Qiang Huo (Forbes Notopterygium). Preclinical pharmacologic experiment and secondary stage clinical trial proved that it has the action of disperse wind-evil and dispel cold as well as supplement Qi forstrengthening exterior. In addition, the toxicologic study showed that it has no evident adverse-toxic effect. Here we report the findings of a multicenter, prospective, double-blind, randomized, placebo controlled, dose-escalation phase II clinical trial to determine the therapeutic efficacy and safety of the SCC in the treatment of patients with wind-cold type common cold.


## 2. Patients and Methods

### 2.1. Study Design

A multicenter, prospective, randomized, double-blind, placebo-controlled, dose-escalation phase II clinical trial was designed to determine the therapeutic efficacy and safety of 0.6 g and 1.2 g of SCC given three times daily for 3 days to patients with wind-cold type common cold. The protocol was reviewed and approved by the independent ethics committees at West China Hospital of Sichuan University (no. TCM-2010-03). In addition, the trial was registered with the Chinese Clinical Trial Registry (no. ChiCTR-TRC-12002296) and was conducted in accordance with the Good Clinical Practice Guidelines and the Declaration of Helsinki [15]. This trial was also authorized by the SFDA of China (no. 2008L11136). All herbs used in this trial were recognized as safe for use by the State Food and Drug Administration (SFDA) of China. We reported the outcomes according to the Consolidated Standards of Reporting Trials statement [16].


### 2.2. Eligibility Criteria

A total of 377 eligible patients were recruited from five centers in China between November 2010 and March 2011. All patients were examined by one of the clinical study respiratory experts and were enrolled into the study according to the inclusion and exclusion criteria described in Table1. All patients gave written informed consent prior to participation. A flowchart illustrating the study procedure is provided in Supplementary material 1 (see Supplementary Material available online at doi:10.1155/2012/254571).Table 1
Inclusion and exclusion criteria.
Inclusion criteria
(1) 18 to 65 years of age
(2) Diagnosis of common cold by a respiratory expert according to relevant criteria and the syndrome criteria of wind-cold type in TCM†
(3) Patient within 48 hours of onset of common cold-like illness
(4) Patient must be able to understand and give written informed consent and report adverse events and concomitant medication for the duration of the study
Exclusion criteria
(1) Patient has suffered from acute viral pharyngitis or laryngitis, acute herpetic pharyngitis or laryngitis, acute conjunctivitis, as well as acute tonsillitis, and so forth
(2) Patient has taken any medication for relief of symptoms prior to study initiation
(3) Patient who  has fever (>38.5°C)
(4) Patient who is on analgesic or anti-inflammatory regimen requiring treatment with analgesics, nonsteroidal anti-inflammatory drugs, or steroids
(5) Patient is pregnant, nursing, or a woman of childbearing potential not practicing adequate contraception. Women, who are uncertain if they are pregnant, may participate in the study, if they undergo a pregnancy test, which shows a negative result
(6) Patient has comorbid condition, uncontrolled metabolic condition or psychiatric condition that might make tolerance or evaluation of the symptoms difficult
†TCM: traditional Chinese medicine.


### 2.3. Randomization and Blinding

A total of 360 of eligible patients met the inclusive criteria and were randomized into group A (0.6 g × 2 capsules of SCC plus 0.6 g × 2 capsule of placebo), group B (1.2 g × 4 capsules of SCC), or group C (1.2 g × 4 capsules of placebo). 120 patients were required placed into each treatment group. Randomization was conducted in blocks of five in a 1 : 1 : 1 ratio using the PRCO PLAN function of the analysis system of SAS (version 6.12 for Windows) by an independent provider not involved in this study. The randomization lists were placed in two sealed envelopes, and the details were unknown to the study investigators and the patients throughout the course of the study. One envelope was kept by Yunnan Institute of Materia Medica (Yunan Province, China), and the other was kept at the study centers to be opened in case of medical emergency.


### 2.4. Treatment Schedule

All randomized patients in group A were required to take 0.6 g of SCC plus 0.6 g placebo three times daily for 3 days; those in group B took 1.2 g of SCC three times daily for 3 days; and those in group C took 1.2 g of placebo three times daily for 3 days. Patients with common cold were diagnosed with “wind-cold type” (which was an inclusion criteria), the corresponding management was designed to disperse wind-evil and dispel cold as well as supplementQifor strengthening exterior. Built on the fundamental principle of TCM, the SCC preparation used in this study contained six primary herbs (Table 2) that were supplied by Yunnan Institute of Materia Medica. The placebo capsule, the main ingredient was starch, was indistinguishable from the SCC in form, color, taste, size, and packaging. All packages were dispensed by an independent research staff member in a separate room after the visit with the respiratory expert.Table 2
Standard formula of SCC.
Chinese name
Pharmaceutical name
The principle of prescription
Source
Pharmacological actions in TCM
Shi Jiaocao
Boenninghausenia  sessilicarpa
Primary ingredients in a prescription
The dried whole plant ofBoenninghausenia  sessilicarpa  Levl
To dispel wind and dry dampness, to regulateQi to relieve pain, and anti-inflammation caused by common cold
Xiao Shancha
Elsholtzia  bodinieri  Van
Minister herb
The dried whole plant ofElsholtzia  bodinieri  Van
To relieve exterior by diaphoresis, to clear away heat-dampness and promote diuresis, to regulateQi to ease the stomach caused by common cold
Huang Qi
Astragalus  membranaceus
Minister herb
The dried root ofAstragalus  membranaceus
To tonifyQi and relieve exterior, to supply Qifor strengthening exterior, to induce diuresis to remove edema, to promote pus discharge and tissue regeneration by strengthening Qi caused by common cold
Yu Xingcao
Houttuynia  cordata  Thunb
Adjuvant and messenger herb
The dried whole plant ofHouttuynia  cordata  Thunb
To clear away heat-toxin caused by common cold
Qian Liguang
Climbing  groundsel  Herb
Adjuvant and messenger herb
The dried whole plant ofClimbing  groundsel  Herb
To clear away heat-toxin caused by common cold
Qiang Huo
Forbes  Notopterygium
Adjuvant and messenger herb
The dried rhizome and root ofForbes  notopterygium
To remove dampness to relieve pain caused by common cold
SCC: Shi-Cha capsule; TCM: traditional Chinese medicine;Qi: vital energy.


### 2.5. Outcome Measures

Patients completed the symptom questionnaire from baseline to day 10 after treatment. These data provided an assessment of all symptom duration, main symptom duration, minor symptom duration, main symptom score, minor symptom score, and cumulative symptom score. The questionnaire consisted of eight symptoms: avertion to cold, clear nasal discharge, arthralgia of extremities, fever, headache, stuffy nose, sneezing, and spiritlessness and weakness. The first two symptoms were main symptom for which the patients provided a graded score (not at all = 0, mild = 3, moderate = 6, severe = 9). The last six symptoms were minor symptom for which the patients provided a graded score (not at all = 0, mild = 1, moderate = 2, severe = 3). The cumulative symptom score was the main symptom score plus the minor symptom score. In addition, tongue proper, tongue fur, and pulse were also assessed (see Supplementary Material 2).


### 2.6. End Points

The primary end point was defined as duration of all symptom. The secondary end points were main symptom duration, minor symptom duration, the changes in main symptom score, minor symptom score, and cumulative symptom score 4 days after the treatment, as well as adverse events. Duration was defined as the number of hours from study enrollment to the last day before the patient answered “No” to the question “Do you think that you are still sick today?”


### 2.7. Followup

In light of the study procedure, patients were seen by a respiratory expert at baseline, day 4, and day 10. During each visit, patients were interviewed by the respiratory expert to ascertain symptoms, compliance, and occurrence of adverse events. In addition, they were in contract with the enrolling research assistant and respiratory expert by telephone throughout the study except for interview. Adherence was assessed by capsule counts and by the daily questionnaire (which asked the patients whether they had taken their capsules and how many capsules they had taken). Adverse events and compliance were monitored. Clinical laboratory evaluation, including routine blood, urine, and stool tests along with hepatic and renal functions, and electrocardiogram, were examined at baseline and at day 4 after treatment to assess the safety of the treatment used for each group.


### 2.8. Sample Size Determination

Based on our experience with TCM in treating common cold and on other similar studies in the literature [17, 18], we assumed the average efficacy π=80%, noninferiority/equivalence boundary value δ=-0.15. The sample size of each group was 88 according to the formula n=2[π(1-π)δ-2](z1-α+z1-β)2  [19]. We allowed for a dropout rate of approximately 10%. Therefore, 360 common cold patients were needed for this study.


### 2.9. Statistical Analysis

All data were documented with Epidata 3.0 by two independent individuals, and the files were locked. The intent-to-treat (ITT) population included all randomized patients who received study medication and attended at least one study visit after the start of treatment. Per-protocol (PP) analysis included all randomized patients who completed study medication and followedup after the start of treatment. The analysis of efficacy was performed in the ITT and PP populations. All quantitative data were expressed as mean ± standard deviation (SD), and one-way analysis of variance (ANOVA) was used to compare the data. A Chi-square test or Fisher’s exact test was performed to calculate differences in qualitative data between the three groups. A Kruskal-WallisH Rank-Sum test was performed to calculate differences in rank data between the three groups. The all symptom duration, main symptom duration, and minor symptom duration were estimated by using the Kaplan-Meier technique and were compared by using the stratified log-rank test. A P value of <0.05 was considered to indicate statistical significance. Data were analyzed using the statistical software Intercooled Stata version 8.2 for Windows (Stata Corporation, College Station, TX, USA).


## 2.1. Study Design

A multicenter, prospective, randomized, double-blind, placebo-controlled, dose-escalation phase II clinical trial was designed to determine the therapeutic efficacy and safety of 0.6 g and 1.2 g of SCC given three times daily for 3 days to patients with wind-cold type common cold. The protocol was reviewed and approved by the independent ethics committees at West China Hospital of Sichuan University (no. TCM-2010-03). In addition, the trial was registered with the Chinese Clinical Trial Registry (no. ChiCTR-TRC-12002296) and was conducted in accordance with the Good Clinical Practice Guidelines and the Declaration of Helsinki [15]. This trial was also authorized by the SFDA of China (no. 2008L11136). All herbs used in this trial were recognized as safe for use by the State Food and Drug Administration (SFDA) of China. We reported the outcomes according to the Consolidated Standards of Reporting Trials statement [16].


## 2.2. Eligibility Criteria

A total of 377 eligible patients were recruited from five centers in China between November 2010 and March 2011. All patients were examined by one of the clinical study respiratory experts and were enrolled into the study according to the inclusion and exclusion criteria described in Table1. All patients gave written informed consent prior to participation. A flowchart illustrating the study procedure is provided in Supplementary material 1 (see Supplementary Material available online at doi:10.1155/2012/254571).Table 1
Inclusion and exclusion criteria.
Inclusion criteria
(1) 18 to 65 years of age
(2) Diagnosis of common cold by a respiratory expert according to relevant criteria and the syndrome criteria of wind-cold type in TCM†
(3) Patient within 48 hours of onset of common cold-like illness
(4) Patient must be able to understand and give written informed consent and report adverse events and concomitant medication for the duration of the study
Exclusion criteria
(1) Patient has suffered from acute viral pharyngitis or laryngitis, acute herpetic pharyngitis or laryngitis, acute conjunctivitis, as well as acute tonsillitis, and so forth
(2) Patient has taken any medication for relief of symptoms prior to study initiation
(3) Patient who  has fever (>38.5°C)
(4) Patient who is on analgesic or anti-inflammatory regimen requiring treatment with analgesics, nonsteroidal anti-inflammatory drugs, or steroids
(5) Patient is pregnant, nursing, or a woman of childbearing potential not practicing adequate contraception. Women, who are uncertain if they are pregnant, may participate in the study, if they undergo a pregnancy test, which shows a negative result
(6) Patient has comorbid condition, uncontrolled metabolic condition or psychiatric condition that might make tolerance or evaluation of the symptoms difficult
†TCM: traditional Chinese medicine.


## 2.3. Randomization and Blinding

A total of 360 of eligible patients met the inclusive criteria and were randomized into group A (0.6 g × 2 capsules of SCC plus 0.6 g × 2 capsule of placebo), group B (1.2 g × 4 capsules of SCC), or group C (1.2 g × 4 capsules of placebo). 120 patients were required placed into each treatment group. Randomization was conducted in blocks of five in a 1 : 1 : 1 ratio using the PRCO PLAN function of the analysis system of SAS (version 6.12 for Windows) by an independent provider not involved in this study. The randomization lists were placed in two sealed envelopes, and the details were unknown to the study investigators and the patients throughout the course of the study. One envelope was kept by Yunnan Institute of Materia Medica (Yunan Province, China), and the other was kept at the study centers to be opened in case of medical emergency.


## 2.4. Treatment Schedule

All randomized patients in group A were required to take 0.6 g of SCC plus 0.6 g placebo three times daily for 3 days; those in group B took 1.2 g of SCC three times daily for 3 days; and those in group C took 1.2 g of placebo three times daily for 3 days. Patients with common cold were diagnosed with “wind-cold type” (which was an inclusion criteria), the corresponding management was designed to disperse wind-evil and dispel cold as well as supplementQifor strengthening exterior. Built on the fundamental principle of TCM, the SCC preparation used in this study contained six primary herbs (Table 2) that were supplied by Yunnan Institute of Materia Medica. The placebo capsule, the main ingredient was starch, was indistinguishable from the SCC in form, color, taste, size, and packaging. All packages were dispensed by an independent research staff member in a separate room after the visit with the respiratory expert.Table 2
Standard formula of SCC.
Chinese name
Pharmaceutical name
The principle of prescription
Source
Pharmacological actions in TCM
Shi Jiaocao
Boenninghausenia  sessilicarpa
Primary ingredients in a prescription
The dried whole plant ofBoenninghausenia  sessilicarpa  Levl
To dispel wind and dry dampness, to regulateQi to relieve pain, and anti-inflammation caused by common cold
Xiao Shancha
Elsholtzia  bodinieri  Van
Minister herb
The dried whole plant ofElsholtzia  bodinieri  Van
To relieve exterior by diaphoresis, to clear away heat-dampness and promote diuresis, to regulateQi to ease the stomach caused by common cold
Huang Qi
Astragalus  membranaceus
Minister herb
The dried root ofAstragalus  membranaceus
To tonifyQi and relieve exterior, to supply Qifor strengthening exterior, to induce diuresis to remove edema, to promote pus discharge and tissue regeneration by strengthening Qi caused by common cold
Yu Xingcao
Houttuynia  cordata  Thunb
Adjuvant and messenger herb
The dried whole plant ofHouttuynia  cordata  Thunb
To clear away heat-toxin caused by common cold
Qian Liguang
Climbing  groundsel  Herb
Adjuvant and messenger herb
The dried whole plant ofClimbing  groundsel  Herb
To clear away heat-toxin caused by common cold
Qiang Huo
Forbes  Notopterygium
Adjuvant and messenger herb
The dried rhizome and root ofForbes  notopterygium
To remove dampness to relieve pain caused by common cold
SCC: Shi-Cha capsule; TCM: traditional Chinese medicine;Qi: vital energy.


## 2.5. Outcome Measures

Patients completed the symptom questionnaire from baseline to day 10 after treatment. These data provided an assessment of all symptom duration, main symptom duration, minor symptom duration, main symptom score, minor symptom score, and cumulative symptom score. The questionnaire consisted of eight symptoms: avertion to cold, clear nasal discharge, arthralgia of extremities, fever, headache, stuffy nose, sneezing, and spiritlessness and weakness. The first two symptoms were main symptom for which the patients provided a graded score (not at all = 0, mild = 3, moderate = 6, severe = 9). The last six symptoms were minor symptom for which the patients provided a graded score (not at all = 0, mild = 1, moderate = 2, severe = 3). The cumulative symptom score was the main symptom score plus the minor symptom score. In addition, tongue proper, tongue fur, and pulse were also assessed (see Supplementary Material 2).


## 2.6. End Points

The primary end point was defined as duration of all symptom. The secondary end points were main symptom duration, minor symptom duration, the changes in main symptom score, minor symptom score, and cumulative symptom score 4 days after the treatment, as well as adverse events. Duration was defined as the number of hours from study enrollment to the last day before the patient answered “No” to the question “Do you think that you are still sick today?”


## 2.7. Followup

In light of the study procedure, patients were seen by a respiratory expert at baseline, day 4, and day 10. During each visit, patients were interviewed by the respiratory expert to ascertain symptoms, compliance, and occurrence of adverse events. In addition, they were in contract with the enrolling research assistant and respiratory expert by telephone throughout the study except for interview. Adherence was assessed by capsule counts and by the daily questionnaire (which asked the patients whether they had taken their capsules and how many capsules they had taken). Adverse events and compliance were monitored. Clinical laboratory evaluation, including routine blood, urine, and stool tests along with hepatic and renal functions, and electrocardiogram, were examined at baseline and at day 4 after treatment to assess the safety of the treatment used for each group.


## 2.8. Sample Size Determination

Based on our experience with TCM in treating common cold and on other similar studies in the literature [17, 18], we assumed the average efficacy π=80%, noninferiority/equivalence boundary value δ=-0.15. The sample size of each group was 88 according to the formula n=2[π(1-π)δ-2](z1-α+z1-β)2  [19]. We allowed for a dropout rate of approximately 10%. Therefore, 360 common cold patients were needed for this study.


## 2.9. Statistical Analysis

All data were documented with Epidata 3.0 by two independent individuals, and the files were locked. The intent-to-treat (ITT) population included all randomized patients who received study medication and attended at least one study visit after the start of treatment. Per-protocol (PP) analysis included all randomized patients who completed study medication and followedup after the start of treatment. The analysis of efficacy was performed in the ITT and PP populations. All quantitative data were expressed as mean ± standard deviation (SD), and one-way analysis of variance (ANOVA) was used to compare the data. A Chi-square test or Fisher’s exact test was performed to calculate differences in qualitative data between the three groups. A Kruskal-WallisH Rank-Sum test was performed to calculate differences in rank data between the three groups. The all symptom duration, main symptom duration, and minor symptom duration were estimated by using the Kaplan-Meier technique and were compared by using the stratified log-rank test. A P value of <0.05 was considered to indicate statistical significance. Data were analyzed using the statistical software Intercooled Stata version 8.2 for Windows (Stata Corporation, College Station, TX, USA).


## 3. Results

### 3.1. Demographic Data and Baseline Characteristics

A total of 377 patients were recruited during a period of five months from November 2010 to March 2011, 360 of these patients met the inclusive criteria, and 120 patients were placed into each treatment group. A total of 26 patients (7.22%) withdrew during the course of the trial: 7 (5.83%) in group A, 7 (5.83%) in group B, and 12 (10%) in group C, respectively (P=0.35). Six patients were withdrawn from the trial because the intervention was ineffective during the treatment period, and 18 patients were withdrawn from the trial because they were lost to followup (Figure 1). There were no significant differences in baseline characteristics in terms of sex ratio, age, weight, height, duration of common cold, body temperature, main symptom score, and cumulative symptom score among the three groups (Table 3).Table 3
Demographic data and baseline characteristics: intent-to-treat analysis.
Group A (n = 114)
Group B (n = 117)
Group C (n = 115)
χ
2
/
F
P values
Sex ratio (male/female)
71/43
76/41
75/40
0.263
0.877†
Age (years) (mean ± SD)
35.98 ± 12.453
36.12 ± 12.465
35.64 ± 12.135
0.046
0.955‡
Body weight (kg) (mean ± SD)
61.12 ± 10.514
60.23 ± 8.855
58.98 ± 9.827
1.387
0.251‡
Height (cm) (mean ± SD)
164.63 ± 8.223
164.36 ± 7.750
164.11 ± 8.266
0.118
0.889‡
Body temperature (°C) (mean ± SD)
36.95 ± 0.451
36.90 ± 0.481
36.98 ± 0.507
0.855
0.426‡
Course (hours) (mean ± SD)
22.75 ± 11.096
24.21 ± 12.104
23.42 ± 11.477
0.516
0.772¶
Main symptoms score (mean ± SD)
Avertion to cold
4.68 ± 1.741
4.59 ± 1.698
4.85 ± 1.713
1.477
0.478¶
Nasal discharge
5.58 ± 1.991
5.26 ± 1.844
5.69 ± 2.002
2.836
0.242¶
Minor symptoms score (mean ± SD)
0.478¶
Arthralgia of extremities
1.33 ± 0.816
1.26 ± 0.770
1.28 ± 0.779
0.298
0.861¶
Fever
0.45 ± 0.705
0.40 ± 0.732
0.49 ± 0.788
1.080
0.583¶
Headache
1.01 ± 0.735
1.04 ± 0.781
0.97 ± 0.725
0.492
0.782¶
Stuffy nose
1.66 ± 0.762
1.47 ± 0.677
1.64 ± 0.752
4.082
0.130¶
Sneezing
1.38 ± 0.803
1.52 ± 0.690
1.42 ± 0.827
2.338
0.311¶
Spiritlessness and weakness
1.18 ± 0.771
1.25 ± 0.684
1.29 ± 0.758
1.102
0.576¶
Cumulative symptoms score (mean ± SD)
17.27 ± 4.700
16.79 ± 4.333
17.63 ± 4.979
0.962
0.383‡
†Chi-square test.
‡One-way analysis of variance.
¶Kruskal-Wallis H test.Figure 1
Flow chart of patient disposition. ITT: intent-to-treat; PP: per-protocol analysis.


### 3.2. All Symptom Duration, Main Symptom Duration, and Minor Symptom Duration

For cohort patients, there was a significant difference in all symptom duration and main symptom duration among three Groups both the ITT and PP analyses (Figures2(a), 2(b), and 2(d); P<0.001). Besides, there was a significant difference in minor symptom duration of arthralgia of extremities, stuffy nose, sneezing, and spiritlessness and weakness among three groups with both the ITT and PP analyses (data not shown, P<0.05). In addition, all symptom duration and main symptom duration showed a slight superiority of group B over group A, although these differences were not statistically significant.Figure 2
The duration of symptom for patients with wind-cold type common cold receiving 0.6 g SCC (group A), 1.2 g SCC (group B), or 1.2 g placebo (group C). (a) All symptom duration; (b) and (c) the duration of avertion to cold; (d) and (e) the nasal discharge.In addition, the main symptom duration and minor symptom duration were determined between patients with SCC treatment and without. There was a significant difference in main symptom duration (Figures2(c) and 2(e); P<0.0001) and minor symptom duration of arthralgia of extremities, stuffy nose, sneezing, as well as spiritlessness and weakness between patients with SCC treatment and without both the ITT and PP analyses (data not shown, P<0.0001).


### 3.3. Cumulative Symptom Score, Main Symptom Score, and Minor Symptom Score

In addition to evaluate the duration of symptom, the symptom score was also compared among three Groups. An improvement in cumulative and individual symptom score was observed from baseline to day 10 in all three groups. The changes from baseline of symptom score at day 4 were compared because the most significant changes in cumulative symptom score and individual symptom score occurred at day 4 after treatment among three groups (Figure3).The symptom score for patients with wind-cold type common cold receiving 0.6 g SCC (group A), 1.2 g SCC (group B), or 1.2 g placebo (group C). (a) The cumulative symptom score; (b) the avertion to cold score; (c) the clear nasal discharge score; (d) the arthralgia of extremities score; (e) the fever score; (f) the headache score; (g) the stuffy nose score; (h) the sneezing score; and (i) the spiritlessness and weakness score.
(a)
(b)
(c)
(d)
(e)
(f)
(g)
(h)
(i)Compared with patients in group C, the ITT and PP analyses showed that patients in groups A and B had significant improvement in change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4 (P<0.0001). In addition, the scores showed a slight superiority of group B over group A at day 4, although these differences were not statistically significant (Table 4).Table 4
Intent-to-treat and per-protocol analyses of main symptom score, minor symptom score, and cumulative symptom score.
Intent-to-treat analysis
Change from baseline to day 4 (mean ± SD)
Group A (n = 114)
Group B (n = 117)
Group C (n = 115)
Main symptom score
8.842 ± 3.453
8.513 ± 3.050
7.330 ± 4.209
P value versus group C
<0.0001
<0.0001
Minor symptom score
5.851 ± 2.839
6.120 ± 2.443
5.157 ± 2.648
P value versus group C
<0.0001
<0.0001
Cumulative symptom score
14.320 ± 5.577
13.890 ± 4.949
11.920 ± 6.090
P value versus group C
<0.0001
<0.0001
Per-protocol analysis
Group A (n = 113)
Group B (n = 113)
Group C (n = 108)
Main symptom score
8.920 ± 3.365
8.522 ± 3.094
7.417 ± 4.212
P value versus group C
<0.0001
<0.0001
Minor symptom score
5.876 ± 2.838
6.053 ± 2.394
5.241 ± 2.696
P value versus group C
<0.0001
<0.0001
Cumulative symptom score
14.420 ± 5.498
13.850 ± 5.016
12.060 ± 6.143
P value versus group C
<0.0001
<0.0001


### 3.4. Safety

There were no deaths during the study. There were one, one, and two patients with adverse effects in group A, group B, and group C, respectively (P=0.774). All patients developed light upper abdominal discomfort accompanied by nausea and vomiting. In these patients, we reduced the dose of the experimental drugs and the symptom gradually eased in the absence of any treatment. In addition, no clinically significant changes were noted in laboratory evaluations or physical examinations. We concluded that there was no significant correlation between the use of SCC and adverse events.


## 3.1. Demographic Data and Baseline Characteristics

A total of 377 patients were recruited during a period of five months from November 2010 to March 2011, 360 of these patients met the inclusive criteria, and 120 patients were placed into each treatment group. A total of 26 patients (7.22%) withdrew during the course of the trial: 7 (5.83%) in group A, 7 (5.83%) in group B, and 12 (10%) in group C, respectively (P=0.35). Six patients were withdrawn from the trial because the intervention was ineffective during the treatment period, and 18 patients were withdrawn from the trial because they were lost to followup (Figure 1). There were no significant differences in baseline characteristics in terms of sex ratio, age, weight, height, duration of common cold, body temperature, main symptom score, and cumulative symptom score among the three groups (Table 3).Table 3
Demographic data and baseline characteristics: intent-to-treat analysis.
Group A (n = 114)
Group B (n = 117)
Group C (n = 115)
χ
2
/
F
P values
Sex ratio (male/female)
71/43
76/41
75/40
0.263
0.877†
Age (years) (mean ± SD)
35.98 ± 12.453
36.12 ± 12.465
35.64 ± 12.135
0.046
0.955‡
Body weight (kg) (mean ± SD)
61.12 ± 10.514
60.23 ± 8.855
58.98 ± 9.827
1.387
0.251‡
Height (cm) (mean ± SD)
164.63 ± 8.223
164.36 ± 7.750
164.11 ± 8.266
0.118
0.889‡
Body temperature (°C) (mean ± SD)
36.95 ± 0.451
36.90 ± 0.481
36.98 ± 0.507
0.855
0.426‡
Course (hours) (mean ± SD)
22.75 ± 11.096
24.21 ± 12.104
23.42 ± 11.477
0.516
0.772¶
Main symptoms score (mean ± SD)
Avertion to cold
4.68 ± 1.741
4.59 ± 1.698
4.85 ± 1.713
1.477
0.478¶
Nasal discharge
5.58 ± 1.991
5.26 ± 1.844
5.69 ± 2.002
2.836
0.242¶
Minor symptoms score (mean ± SD)
0.478¶
Arthralgia of extremities
1.33 ± 0.816
1.26 ± 0.770
1.28 ± 0.779
0.298
0.861¶
Fever
0.45 ± 0.705
0.40 ± 0.732
0.49 ± 0.788
1.080
0.583¶
Headache
1.01 ± 0.735
1.04 ± 0.781
0.97 ± 0.725
0.492
0.782¶
Stuffy nose
1.66 ± 0.762
1.47 ± 0.677
1.64 ± 0.752
4.082
0.130¶
Sneezing
1.38 ± 0.803
1.52 ± 0.690
1.42 ± 0.827
2.338
0.311¶
Spiritlessness and weakness
1.18 ± 0.771
1.25 ± 0.684
1.29 ± 0.758
1.102
0.576¶
Cumulative symptoms score (mean ± SD)
17.27 ± 4.700
16.79 ± 4.333
17.63 ± 4.979
0.962
0.383‡
†Chi-square test.
‡One-way analysis of variance.
¶Kruskal-Wallis H test.Figure 1
Flow chart of patient disposition. ITT: intent-to-treat; PP: per-protocol analysis.


## 3.2. All Symptom Duration, Main Symptom Duration, and Minor Symptom Duration

For cohort patients, there was a significant difference in all symptom duration and main symptom duration among three Groups both the ITT and PP analyses (Figures2(a), 2(b), and 2(d); P<0.001). Besides, there was a significant difference in minor symptom duration of arthralgia of extremities, stuffy nose, sneezing, and spiritlessness and weakness among three groups with both the ITT and PP analyses (data not shown, P<0.05). In addition, all symptom duration and main symptom duration showed a slight superiority of group B over group A, although these differences were not statistically significant.Figure 2
The duration of symptom for patients with wind-cold type common cold receiving 0.6 g SCC (group A), 1.2 g SCC (group B), or 1.2 g placebo (group C). (a) All symptom duration; (b) and (c) the duration of avertion to cold; (d) and (e) the nasal discharge.In addition, the main symptom duration and minor symptom duration were determined between patients with SCC treatment and without. There was a significant difference in main symptom duration (Figures2(c) and 2(e); P<0.0001) and minor symptom duration of arthralgia of extremities, stuffy nose, sneezing, as well as spiritlessness and weakness between patients with SCC treatment and without both the ITT and PP analyses (data not shown, P<0.0001).


## 3.3. Cumulative Symptom Score, Main Symptom Score, and Minor Symptom Score

In addition to evaluate the duration of symptom, the symptom score was also compared among three Groups. An improvement in cumulative and individual symptom score was observed from baseline to day 10 in all three groups. The changes from baseline of symptom score at day 4 were compared because the most significant changes in cumulative symptom score and individual symptom score occurred at day 4 after treatment among three groups (Figure3).The symptom score for patients with wind-cold type common cold receiving 0.6 g SCC (group A), 1.2 g SCC (group B), or 1.2 g placebo (group C). (a) The cumulative symptom score; (b) the avertion to cold score; (c) the clear nasal discharge score; (d) the arthralgia of extremities score; (e) the fever score; (f) the headache score; (g) the stuffy nose score; (h) the sneezing score; and (i) the spiritlessness and weakness score.
(a)
(b)
(c)
(d)
(e)
(f)
(g)
(h)
(i)Compared with patients in group C, the ITT and PP analyses showed that patients in groups A and B had significant improvement in change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4 (P<0.0001). In addition, the scores showed a slight superiority of group B over group A at day 4, although these differences were not statistically significant (Table 4).Table 4
Intent-to-treat and per-protocol analyses of main symptom score, minor symptom score, and cumulative symptom score.
Intent-to-treat analysis
Change from baseline to day 4 (mean ± SD)
Group A (n = 114)
Group B (n = 117)
Group C (n = 115)
Main symptom score
8.842 ± 3.453
8.513 ± 3.050
7.330 ± 4.209
P value versus group C
<0.0001
<0.0001
Minor symptom score
5.851 ± 2.839
6.120 ± 2.443
5.157 ± 2.648
P value versus group C
<0.0001
<0.0001
Cumulative symptom score
14.320 ± 5.577
13.890 ± 4.949
11.920 ± 6.090
P value versus group C
<0.0001
<0.0001
Per-protocol analysis
Group A (n = 113)
Group B (n = 113)
Group C (n = 108)
Main symptom score
8.920 ± 3.365
8.522 ± 3.094
7.417 ± 4.212
P value versus group C
<0.0001
<0.0001
Minor symptom score
5.876 ± 2.838
6.053 ± 2.394
5.241 ± 2.696
P value versus group C
<0.0001
<0.0001
Cumulative symptom score
14.420 ± 5.498
13.850 ± 5.016
12.060 ± 6.143
P value versus group C
<0.0001
<0.0001


## 3.4. Safety

There were no deaths during the study. There were one, one, and two patients with adverse effects in group A, group B, and group C, respectively (P=0.774). All patients developed light upper abdominal discomfort accompanied by nausea and vomiting. In these patients, we reduced the dose of the experimental drugs and the symptom gradually eased in the absence of any treatment. In addition, no clinically significant changes were noted in laboratory evaluations or physical examinations. We concluded that there was no significant correlation between the use of SCC and adverse events.


## 4. Discussion

To our knowledge, this is the first large randomized, prospective, double-blind, placebo-controlled, dose-escalation trial designated to evaluate the efficacy and safety of TCM in an adult population from China. Our study demonstrated that SCC was efficacious and safe for the management of wind-cold type common cold. Patients receiving 0.6 g and 1.2 g of SCC treatment three times daily demonstrated significant improvement in the symptom duration and change from baseline of symptom score compared to patients receiving the placebo at day 4. Patients receiving 1.2 g of SCC three times daily showed a slight benefit in their symptom duration and change from baseline of symptom score over patients receiving 0.6 g of SCC three times daily during treatment, although this difference was not statistically significant.To date, there are no validated strategies for the treatment of common cold, and current therapy focuses on symptom relief. This has led to high patient dissatisfaction and frustration with current treatments for common cold. Thus, there is a need for simple, safe, and effective first-line therapies to treat the multiple symptoms of patients with this disorder. TCM stresses differentiation of symptoms and signs; it considers the human being to be an organic entirety and treatment should be emphasized on the entirety. Besides, TCM counts on the synergetic effects of the herbs, which have a general spectra of action. Therefore, TCM practitioners usually use a substantial number of herbs to treat various conditions including common cold, and this will overcome the shortcomings of Western medicine.TCM theory holds that lung is in charge of skin and hair and keeps the dispersing function, skin and hair damage will result in dysfunction of lung with defensiveQi, and lung fails to disperse and descend, eventually leading to common cold. Wind-cold type common cold is mainly manifested as aversion to cold, clear nasal discharge, arthralgia of extremities, fever, headache, stuffy nose, sneezing, spiritlessness and weakness, pale tongue, white fur, and floating pulse according to the fundamental principles of TCM. In this study, wind-cold type common cold patients with were selected for treatment, and the herbal recipe of the SCC, which claimed to disperse wind-evil and dispel cold as well as supply Qi forstrengthening exterior, was designed for these patients according to these principles.The SCC formula contains six herbs includingBoenninghausenia sessilicarpa, Elsholtzia bodinieri Van, Astragalus membranaceus, Houttuynia cordata Thunb, Climbing groundsel Herb, and Forbes Notopterygium. After the outbreak of severe acute respiratory syndrome (SARS) in late 2002, TCM has attracted more attention from researchers who endeavor to search for effective antiviral agents and it may be a good candidate with special characteristics for an antivirus [20]. The SCC formula concurred with published pharmacological data which showed that TCM formula can inhibit growth of a variety of virus as well as bacteria [21, 22]. In addition, several previous studies were consistent with our results which showed that TCM formula might be able to improve symptoms more than placebo for patients with common cold [17, 18, 23–25]. However, all studies to date have had important limitation including lack of objective validated outcome measures for common cold [26]. In this study, the duration of symptom and symptom score were used to evaluate the efficacy of SCC, which found not only a significant benefit in shortening the duration symptom, but also decrease of  the symptom score from the treatment of SCC for patients with wind-cold type common cold.Popular opinion confirms that the general public believes TCM to be safe, to cause fewer side effects, and to be less likely to cause dependency. In our study, only two patients who were receiving 0.6 g and 1.2 g of SCC three time daily reported light upper abdominal pain, respectively. Therefore, we concluded that there was no significant correlation between the use of the SCC and adverse events. Nevertheless, many herbs can be toxic, especially in high quantities and with frequent use. Furthermore, herb-synthetic drug interactions can be problematic. Hence, the analysis of adverse effects of TCM for treating common cold is indeed very important.This study had some potential weaknesses. Only SCC formula for the treatment of common cold with wind-cold type was determined in this study, the outcomes could not be generalized to other herbal formula for the treatment of common cold or other types. The formulation and dosage of SCC standardized, which might not fully reflect the normal practice of TCM which often alters the formula by removing or adding specific herbs according to the patient’s body constitution. However, this finding supports the premise that it was of sufficient study to assess the benefit and safety of TCM for the treatment of common cold.In conclusion, during a treatment period of 3 days, the SCC significantly improved the symptom duration and the changes in symptom score in patients with wind-cold type common cold. Patients receiving 1.2 g of SCC three times daily showed a slight benefit of these end points over patients receiving 0.6 g of SCC three times daily during treatment, although this difference was not statistically significant. Larger trials are required to fully assess the benefits and safety of the use of the two dosages of the SCC for treating wind-cold type common cold.



---

*Source: 254571-2012-12-27.xml*